JESSICA BELL: Open Payments
NPI 1700409711 · HARRISBURG, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,904 in 227 payments from 21 companies in 2025. Trend: 2023 $2,278 · 2024 $2,892 · 2025 $3,904
Food & beverage: $3,820Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 45 | $912 |
| Janssen Biotech, Inc. | 49 | $772 |
| Madrigal Pharmaceuticals | 14 | $490 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 25 | $275 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $222 |
| Regeneron Healthcare Solutions, Inc. | 14 | $214 |
| Novo Nordisk Inc | 7 | $197 |
| Celltrion USA Inc. | 13 | $195 |
| Ipsen Biopharmaceuticals, Inc | 7 | $110 |
| Lilly USA, LLC | 5 | $103 |
Products named: TREMFYA, REZDIFFRA, RINVOQ, DUPIXENT, XIFAXAN, LINZESS, Wegovy, VEGZELMA.
Industry payments across PA — which companies pay providers there.
